Treatment of polydrug-using opiate dependents during withdrawal: towards a standardisation of treatment

Kristensen, Øistein; Lølandsmo, Terje; Isaksen, Åse; Vederhus, John-Kåre; Clausen, Thomas
January 2006
BMC Psychiatry;2006, Vol. 6, p54
Academic Journal
Background: The growing tendency among opioid addicts to misuse multiple other drugs should lead clinicians and researchers to search for new pharmacological strategies in order to prevent life-threatening complications and minimize withdrawal symptoms during polydrug detoxification. Methods: A non-randomised, open-label in-patient detoxification study was used to compare the short-time efficacy of a standardised regimen comprising 6 days Buprenorphine and 10 days Valproate (BPN/VPA) (n = 12) to a control group (n = 50) who took a 10-day traditional Clonidine/Carbamazepine (CLN/CBZ) regimen. Sixty-two dependent subjects admitted to a detoxification unit were included, all dependent on at least opioids and benzodiazepines. Other dependencies were not excluded. Results: In the BPN/VPA group, 8 out of 12 patients (67%) completed treatment compared with 25 of 50 patients (50%) in the CLN/CBZ group; this difference between the groups was nonsignificant (p = 0.15). Withdrawal symptoms were reduced in both groups, but only the BPN/VPA group achieved a reduction in withdrawal symptoms from day one. The difference between the two groups was significantly in favour of the BPN/VPA group for days 2 (p < 0.001), 3 (p < 0.05), 4 (p < 0.001), 5 (p < 0.01), 7 (p < 0.01) and 8 (p < 0.05). The BPN/VPA combination did not affect blood pressure, pulse or liver function, and the total burden of side-effects was experienced as modest. There appeared to be no pharmacological interactions of clinical concern, based on measurement of Buprenorphine and Valproate serum levels. Both the patients and the staff were satisfied with the standardised treatment combination. Conclusion: Overall, the combination of Buprenorphine and Valproate seems to be a safe and promising method for treating multiple drug withdrawal symptoms. The results of this study suggest that the BPN/VPA combination is potentially a better detoxification treatment for polydrug withdrawal than the traditional treatment with Clonidine and Carbamazepine. However, a randomised, double-blind study with a larger sample size to confirm our results is recommended.


Related Articles

  • TRANSCUTANEOUS ELECTRIC ACUPOINT STIMULATION HELPS OPIOID DETOXIFICATION. Yanyi Wang // Australian Journal of Acupuncture & Chinese Medicine;2010, Vol. 5 Issue 2, p50 

    The article presents a study on the use of transcutaneous electric acupoint stimulation (TEAS) for opioid detoxification. The study aims to evaluate whether TEAS help patients with opioid dependence maintain abstinence from drug use or improve withdrawal symptoms, physical pain and health...

  • Anticraving Medications.  // Child & Adolescent Psychopharmacology News;2005, Vol. 10 Issue 3, p6 

    Discusses a paper, written by C. O'Brian and published in the "American Journal of Psychiatry," addressing the concepts of detoxification and craving reduction as important targets for medication management in drug addiction. Role of psychotherapies; Paper's encouragement of the rational use of...

  • Methadone Doses upon Multiple Readmissions to Inpatient Detoxification: Clinical Evidence for Very Moderate Opioid Tolerance. Madlung, Ekkehard; Haring, Christian; Crespo, Jose A.; Saria, Alois; Grubinger, Petra; Zernig, Gerald // Pharmacology;2006, Vol. 78 Issue 1, p38 

    Escalation of drug use by addicts has traditionally been interpreted as tolerance to the drug’s effects. On the basis of animal behavioral data, several groups have recently proposed alternative explanations, i.e., that such an escalation of drug dose might not be based on tolerance but...

  • Comparative Trial to Study the Effectiveness of Clonidine Hydrochloride and Buprenorphine-Naloxone in Opioid Withdrawal - A Hospital Based Study. SAJAD HUSSAIN, SYED; FARHAT, SAMINA; HASSAN RAT, YASIR; ABBAS, ZAFFAR // Journal of Clinical & Diagnostic Research;Jan2015, Vol. 9 Issue 1, p1 

    Objectives: Prevalence of opioid addiction has alarmingly increased over the recent years. In South Asian region alone there are more than 10 million opioid abusers amounting to 2% of world population. Detoxification remains to be the first step for the successful treatment of opioid addiction....

  • Anesthesia-Assisted vs Buprenorphine- or Clonidine-Assisted Heroin Detoxification and Naltrexone Induction: A Randomized Trial. Collins, Eric D.; Kleber, Herbert D.; Whittington, Robert A.; Heitler, Nicole E. // JAMA: Journal of the American Medical Association;8/24/2005, Vol. 294 Issue 8, p903 

    Context Rapid opioid detoxification with opioid antagonist induction using general anesthesia has emerged as an expensive, potentially dangerous, unproven approach to treat opioid dependence. Objective To determine how anesthesia-assisted detoxification with rapid antagonist induction for heroin...

  • Comparison of Alcohol-Dependent Patients with and without Physiological Dependence. Lejoyeux, Michel; Claudon, Micheline; McLoughlin, Mary; Adès, Jean // European Addiction Research;2001, Vol. 7 Issue 4, p198 

    Sociodemographic and clinical characteristics of alcohol-dependent patients with or without physiological dependence (e.g. tolerance to alcohol or withdrawal) were compared. 186 consecutive alcohol-dependent patients hospitalized for alcohol detoxification were assessed. Diagnosis of alcohol...

  • Post-Treatment Outcomes of Buprenorphine Detoxification in Community Settings: A Systematic Review. Horspool, Michelle J.; Seivewright, Nicholas; Armitage, Christopher J.; Mathers, Nigel // European Addiction Research;2008, Vol. 14 Issue 4, p179 

    A systematic review was undertaken to examine studies of buprenorphine detoxification that has included post-treatment outcomes as well as more immediate aspects of progress. Studies were required to report details of buprenorphine withdrawal regime and post-treatment outcomes including...

  • Short-course diphenoxylate hydrochloride for treatment of methadone withdrawal symptoms. Ives, T.J.; Stults, C.C. // British Journal of Psychiatry;Nov83, Vol. 143, p513 

    The authors conducted a preliminary trial of a 5-day course of diphenoxylate in the treatment of out-patients with methadone withdrawal symptoms. Diphenoxylate provided substantial relief from detoxification symptoms with no drug-associated adverse effects.

  • The pharmacological treatment of opioid addiction—a clinical perspective. Lobmaier, Philipp; Gossop, Michael; Waal, Helge; Bramness, Jorgen // European Journal of Clinical Pharmacology;Jun2010, Vol. 66 Issue 6, p537 

    This article reviews the main pharmacotherapies that are currently being used to treat opioid addiction. Treatments include detoxification using tapered methadone, buprenorphine, adrenergic agonists such as clonidine and lofexidine, and forms of rapid detoxification. In opioid maintenance...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics